Castle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 1,034 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Tobin Juvenal sold 1,034 shares of the business’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $34.20, for a total value of $35,362.80. Following the sale, the insider directly owned 52,007 shares of the company’s stock, valued at approximately $1,778,639.40. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Down 0.8%

Shares of Castle Biosciences stock traded down $0.27 during trading hours on Thursday, reaching $35.26. The stock had a trading volume of 522,288 shares, compared to its average volume of 398,525. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -53.42 and a beta of 0.99. Castle Biosciences, Inc. has a 1 year low of $17.72 and a 1 year high of $44.28. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. The firm has a 50 day simple moving average of $32.08 and a two-hundred day simple moving average of $26.14.

Get Castle Biosciences alerts:

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.34. The business had revenue of $99.86 million during the quarter, compared to analysts’ expectations of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. As a group, equities research analysts anticipate that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Institutional Trading of Castle Biosciences

A number of hedge funds have recently made changes to their positions in CSTL. BlackRock Inc. acquired a new position in shares of Castle Biosciences during the second quarter worth $78,513,000. Summit Partners Public Asset Management LLC grew its holdings in Castle Biosciences by 164.7% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after purchasing an additional 658,725 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in Castle Biosciences during the 2nd quarter worth $15,440,000. AIGH Capital Management LLC purchased a new stake in Castle Biosciences during the 2nd quarter worth $13,001,000. Finally, Renaissance Technologies LLC increased its stake in Castle Biosciences by 8.1% during the 1st quarter. Renaissance Technologies LLC now owns 532,800 shares of the company’s stock worth $13,080,000 after buying an additional 39,700 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

CSTL has been the subject of several recent research reports. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research report on Friday, July 31st. Wall Street Zen raised shares of Castle Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 26th. Roth Capital began coverage on Castle Biosciences in a report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price target for the company. Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. Finally, BTIG Research boosted their price objective on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Read Our Latest Analysis on Castle Biosciences

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians make more informed decisions about cancer diagnosis and treatment. Its products use genomic and molecular information to assess disease characteristics, patient risk and likely outcomes.

The company’s portfolio includes DecisionDx-Melanoma, which helps assess the risk of metastasis in patients with cutaneous melanoma; DecisionDx-SCC, which evaluates metastatic risk in certain patients with cutaneous squamous cell carcinoma; and MyPath Melanoma, which assists in distinguishing benign from malignant melanocytic lesions.

Featured Articles

• Five stocks we like better than Castle Biosciences
• Everyone in AI Is Quietly Copying Palantir’s Playbook
• Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
• JPMorgan Bets on Genius Sports as the Market Loses Patience
• Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.